TGF-β Superfamily and Structure
The TGF-β superfamily is the largest family of secreted signaling proteins in metazoans, comprising 33 members in humans. Members share a conserved C-terminal "cystine knot" growth factor domain (~110 amino acids, 7 invariant cysteines) and signal through heteromeric serine/threonine kinase receptor complexes. Major branches:
| Subfamily | Members | Key Functions |
|---|---|---|
| TGF-β | TGF-β1, TGF-β2, TGF-β3 | Fibrosis, immune suppression, wound healing, EMT; all three signal via ALK5/TβRII → SMAD2/3. TGF-β1 most abundant and widely expressed; TGF-β3 important in palatogenesis (cleft palate when absent); TGF-β2 in eye/cardiac development |
| BMPs (bone morphogenetic proteins) | BMP2, BMP4, BMP5–9, BMP15 (20 members) | Osteogenesis, cartilage formation, neural patterning (BMP4 — dorso-ventral axis), vascular regulation (BMP9/10 — hepatic ligands for ALK1/ENG); signal via ALK1/2/3/6 → SMAD1/5/8 |
| Activins | Activin A, B, AB, C, E | FSH secretion (gonadotropin regulation), erythropoiesis, wound healing, inflammatory modulation; signal via ALK4 → SMAD2/3 |
| GDFs (growth and differentiation factors) | GDF5/6/7 (joint/tendon formation), GDF8/myostatin (muscle mass suppressor), GDF11 (aging), GDF15 (stress cytokine, cachexia) | Musculoskeletal development; GDF8/myostatin inhibits skeletal muscle growth via ActRIIB → ALK4/5 → SMAD2/3; GDF15 elevated in cancer cachexia, heart failure, metformin treatment |
| AMH / MIS | Anti-Müllerian hormone | Regression of Müllerian ducts in male fetal development; clinical marker for ovarian reserve |
| Nodal | Nodal | Left-right body axis determination, mesoderm induction; signals via ALK4/7 + EGF-CFC co-receptor → SMAD2/3 |
TGF-β1 Protein Structure and Latency
TGF-β1 is synthesized as a 390 amino acid precursor (pre-pro-TGF-β1). The signal peptide is cleaved, yielding pro-TGF-β1; furin in the trans-Golgi cleaves the prodomain (latency-associated peptide, LAP) from the growth factor domain, but the two remain noncovalently associated as the small latent complex (SLC) — a disulfide-linked homodimer of mature TGF-β1 with its LAP. LAP wraps around the growth factor domain and sterically blocks receptor binding. The SLC is additionally disulfide-linked to LTBP-1, -3, or -4 (latent TGF-β binding proteins) to form the large latent complex (LLC), which is secreted and sequestered in the ECM via LTBP's fibronectin/fibrillin-1 binding domains.
Latent TGF-β activation — the step that determines when and where TGF-β signals — occurs via multiple mechanisms:
- Integrin αvβ6 (on epithelial cells, especially injured lung/kidney epithelium): RGDLXXL motif in LAP binds integrin → cell-generated traction force deforms LAP → release of active TGF-β; most important mechanism in lung fibrosis (IPF)
- Integrin αvβ8 (on astrocytes, dendritic cells): Presents latent TGF-β to MT1-MMP at cell surface for proteolytic cleavage
- MMP-2 and MMP-9: Cleave LAP at specific sites to release active TGF-β; important in tumor microenvironment and wound healing
- Thrombospondin-1 (TSP-1): Binds LSKL motif in LAP → conformational change → active TGF-β; important in platelets and endothelial cells during injury
- Extreme pH and ROS: Acidic conditions (tumor microenvironment) and reactive oxygen species can directly unfold LAP
Canonical SMAD Signaling
The canonical TGF-β pathway is defined by the activation of receptor-regulated SMADs (R-SMADs) following receptor kinase activation:
Receptor Complex Assembly and Kinase Activation
Active TGF-β1 homodimer binds the TGF-β type II receptor (TβRII) — a constitutively active serine/threonine kinase. TβRII-TGF-β1 complex recruits and transphosphorylates the TGF-β type I receptor (TβRI/ALK5) in the GS domain (Gly-Ser rich juxtamembrane region) at Ser/Thr residues. Active ALK5 phosphorylates R-SMADs.
Different type I receptors (ALKs) specify downstream SMAD pathway:
- ALK5 (TβRI): Activated by TGF-β1/2/3 → phosphorylates SMAD2 and SMAD3 (fibrosis, EMT, immune suppression)
- ALK1: Activated by TGF-β1/BMP9/10 in endothelial cells → phosphorylates SMAD1/5/8 (pro-angiogenic; ALK1 mutations → hereditary hemorrhagic telangiectasia/HHT; endoglin/ENG is co-receptor)
- ALK2/3/6: BMP-specific ALKs → SMAD1/5/8 (bone formation, development)
- ALK4/7: Activin/Nodal receptors → SMAD2/3
SMAD Activation and Nuclear Signaling
ALK5 phosphorylates SMAD2 at C-terminal SxS motif (Ser465/Ser467) and SMAD3 (Ser423/Ser425). Phosphorylated SMAD2/3 dissociate from the receptor → form heterotrimeric complexes with the co-SMAD SMAD4 → nuclear import via importin-β3/α → binding to SMAD binding elements (SBE; CAGACA consensus) in target gene promoters → recruitment of co-activators (p300/CBP, PCAF histone acetyltransferases) or co-repressors (HDAC, Ski/SnoN) depending on cellular context.
Key TGF-β/SMAD target genes in fibrosis: COL1A1 (collagen Iα1), COL3A1, ACTA2 (α-SMA), CTGF/CCN2, FN1 (fibronectin), SERPINE1 (PAI-1), MMP-2/9 (paradoxically both induced and later suppressed by SMAD).
Key TGF-β/SMAD target genes in growth arrest: CDKN2B/p15 (CDK4/6 inhibitor) and CDKN1A/p21 (CDK2 inhibitor) — both strongly induced by SMAD3 → G1 cell cycle arrest. This is the tumor suppressor function of TGF-β.
Inhibitory SMADs — Negative Feedback
SMAD7 is the primary inhibitor of TGF-β/SMAD signaling. SMAD7 is a transcriptional target of TGF-β/SMAD3 itself — creating a negative feedback loop. SMAD7 acts by: (1) competing with R-SMADs for receptor interaction, preventing phosphorylation; (2) recruiting SMURF1 and SMURF2 (E3 ubiquitin ligases) to TβRI → ubiquitin-mediated receptor degradation; (3) recruiting PP1c phosphatase to dephosphorylate TβRI. In IPF and fibrotic disease, SMAD7 expression is reduced, removing this brake and sustaining TGF-β signaling. SMAD6 preferentially inhibits BMP/SMAD1/5/8 signaling via analogous mechanisms.
Non-SMAD Signaling Pathways
TGF-β activates multiple non-SMAD pathways, primarily through TRAF6 (TNFR-associated factor 6) recruited to the receptor complex and through direct activation of kinases by TβRI/TβRII:
| Pathway | Mechanism | Functional Outcome |
|---|---|---|
| TRAF6/TAK1 → NF-κB | TβRI binds TRAF6 → TRAF6 Lys63-polyubiquitylation → TAK1 (MAP3K7) activation → IKK complex → IκBα phosphorylation/degradation → NF-κB nuclear translocation | Pro-inflammatory gene expression; survival signals; context-dependent induction of IL-6, TNF-α, MMP-9. Relevant in epithelial cells and macrophages where TGF-β drives inflammatory phenotypes despite SMAD-mediated growth arrest |
| TAK1 → p38 MAPK / JNK | TAK1 → MKK3/6 → p38; TAK1 → MKK4/7 → JNK | p38: stress-responsive fibroblast activation, EMT (α-SMA induction), apoptosis in epithelial cells. JNK: EMT transcription factor (Snail, Twist) induction; TGF-β-induced apoptosis via Bim/Bad phosphorylation. p38 and JNK often cooperate with SMAD3 to maximize EMT gene responses |
| PI3K/Akt/mTOR | TβRI/II directly phosphorylates and activates PI3K regulatory subunit p85 → Akt → mTORC1. Also indirect: TβRI → TRAF6 → PI3K | Cell survival (anti-apoptotic via BAD phosphorylation, Mcl-1 upregulation); cell migration and invasion; mTORC1-dependent protein synthesis for fibrotic ECM production. PI3K/Akt cooperates with SMAD2/3 in EMT and resistance to TGF-β-induced apoptosis in cancer cells |
| Rho/ROCK | TGF-β → RhoA GTP loading (via direct receptor interaction or SMAD-independent mechanisms) → ROCK1/2 → LIM kinase → cofilin phosphorylation (inactivation) → F-actin polymerization; also ROCK → MLC phosphorylation → increased cell contractility | Stress fiber formation (α-SMA incorporation), cell contraction (myofibroblast phenotype), cell migration and invasion (EMT), mechanosensing amplification. ROCK inhibitors (fasudil, Y-27632) reduce TGF-β-driven fibrosis in animal models |
| Src/ERK | TβRII contains a Src-homology 2 (SH2) binding motif → direct Src recruitment and activation → Grb2/Sos → Ras → Raf → MEK → ERK1/2 | Cell proliferation signals (paradoxically co-exist with SMAD-mediated growth arrest in non-epithelial cells); synergy with EGFR signaling in cancer; regulation of SMAD nucleo-cytoplasmic shuttling via ERK-mediated SMAD linker phosphorylation (at Thr179/Ser204/Ser208 of SMAD3) → attenuated transcriptional activity |
| β-catenin/Wnt crosstalk | TGF-β/SMAD3 complex can directly bind β-catenin in the nucleus → cooperative gene activation; SMAD3 also stabilizes β-catenin via inhibition of GSK-3β (APC/Axin/GSK-3β destruction complex) | Fibroblast-to-myofibroblast transition; AT2 cell fate decisions in lung injury; Wnt/β-catenin and TGF-β cooperatively drive fibrosis and EMT in multiple organs. IPF patient lungs show co-activation of Wnt and TGF-β targets |
Pleiotropic Biological Functions
Anti-Proliferative / Tumor Suppressor Activity
In normal epithelial cells, TGF-β induces G1 cell cycle arrest via SMAD3-dependent transcriptional induction of p15/CDKN2B (inhibits CDK4/6 → prevents pRb phosphorylation → E2F remains bound to pRb → no S-phase entry) and p21/CDKN1A (inhibits CDK2 → reinforces G1 arrest). Simultaneously, SMAD3 represses c-Myc and Id proteins that drive proliferation. This makes TGF-β a potent inhibitor of epithelial cell proliferation — the basis for its tumor-suppressor role in early carcinogenesis.
Epithelial-Mesenchymal Transition (EMT)
TGF-β is the canonical inducer of EMT — the process by which epithelial cells lose apical-basal polarity, disrupt cell-cell junctions (E-cadherin/CDH1 downregulation), and acquire a mesenchymal gene expression program (N-cadherin/CDH2, vimentin/VIM, fibronectin/FN1, α-SMA/ACTA2). EMT transcription factors induced by TGF-β/SMAD3 + non-SMAD pathways:
- Snail1 (SNAI1): Direct SMAD3 target; zinc finger transcriptional repressor of E-cadherin (CDH1); also represses claudins, occludins. Induced within hours of TGF-β stimulation.
- Slug/Snail2 (SNAI2): Similar mechanism; more relevant in wound healing and tumor invasion contexts
- ZEB1 and ZEB2: Zinc finger E-box binding homeobox proteins; bind E-cadherin and claudin promoters; ZEB1 is also repressed by miR-200 family microRNAs (miR-200a/b/c, miR-141, miR-429) — the ZEB/miR-200 double-negative feedback loop is the key switch controlling epithelial-mesenchymal plasticity
- Twist1: bHLH transcription factor induced by TGF-β/non-SMAD pathways; important in cancer invasion and metastasis
Immune Suppression and Treg Induction
TGF-β is the dominant cytokine for peripheral immune tolerance:
- Foxp3+ Treg induction: TGF-β1 + IL-2 (+ retinoic acid in mucosal tissues) → SMAD3/NFAT → Foxp3 transcription → induction of regulatory T cells. Tregs suppress CD4 and CD8 T cells via TGF-β, IL-10, and CTLA-4 contact suppression.
- Th17 balance: TGF-β alone → Treg; TGF-β + IL-6 → SMAD3/STAT3 → RORγt → Th17 differentiation (pro-inflammatory). The Treg/Th17 balance controlled by TGF-β + cytokine context is critical in autoimmunity and cancer.
- NK/CTL suppression: TGF-β directly inhibits perforin/granzyme B expression in CD8+ CTLs and NK cells; also suppresses NKG2D expression → reduced cytotoxic activity against tumor cells
- Macrophage skewing: TGF-β promotes M2 (anti-inflammatory, pro-repair) macrophage polarization; suppresses M1 killing functions; contributes to immunosuppressive tumor microenvironment
Wound Healing and Fibrosis
TGF-β1 (released by platelets in the initial injury response) orchestrates wound healing: fibroblast recruitment → myofibroblast differentiation (α-SMA, collagen production, wound contraction) → VEGF induction (angiogenesis) → provisional matrix remodeling. In normal healing, TGF-β signaling is self-limited by SMAD7 feedback and myofibroblast apoptosis as the wound closes. In fibrosis, persistent TGF-β1 signaling — from ongoing injury, ER stress, senescent cells, or autocrine loops — prevents myofibroblast apoptosis and drives progressive ECM accumulation (see fibrosis.html).
TGF-β Paradox in Cancer
TGF-β exhibits a striking contextual duality in cancer — tumor suppressor in early carcinogenesis vs. tumor promoter in advanced cancer:
Tumor Suppressor Phase (Early)
In normal epithelium and early-stage cancer with intact SMAD4, TGF-β enforces G1 arrest (p15/p21 induction), induces apoptosis, and suppresses oncogene-driven proliferation. SMAD4 mutations (loss of heterozygosity 18q21.2) occur in ~55% of PDACs and ~15% of CRCs — inactivating the SMAD4 co-SMAD disrupts all canonical TGF-β growth-arrest signals. Inactivating mutations in TβRII (microsatellite instability-driven frameshift mutations in HNPCC/Lynch syndrome colorectal cancers) similarly abolish growth arrest without eliminating pro-tumorigenic TGF-β responses.
Tumor Promoter Phase (Advanced)
In advanced tumors with KRAS mutations, PI3K activation, or SMAD4 loss, TGF-β no longer arrests growth but retains and may amplify pro-tumorigenic functions:
- EMT and invasion: TGF-β drives Snail/ZEB1 → loss of E-cadherin → dissemination of circulating tumor cells
- Immunosuppression: TGF-β in the tumor microenvironment (TME) suppresses CD8+ T cell function, induces Treg infiltration, and impairs NK cell cytotoxicity → immune escape and checkpoint immunotherapy resistance
- Angiogenesis: TGF-β1 induces VEGF-A in stromal fibroblasts and tumor cells → tumor vasculogenesis; ALK1 signaling in endothelial cells is specifically pro-angiogenic
- Bone metastasis: TGF-β released from bone matrix by osteoclast activity → breast/prostate tumor cell TGF-β signaling → PTHrP production → further osteoclast activation: the "vicious cycle" of bone metastasis
- Cancer-associated fibroblasts (CAFs): Tumor cell-derived TGF-β activates stromal fibroblasts → CAFs → create desmoplastic ECM → physical barrier to T cell infiltration and drug delivery (especially relevant in pancreatic cancer)
Therapeutic Targeting of TGF-β
| Agent | Class / Target | Mechanism | Clinical Context |
|---|---|---|---|
| Galunisertib (LY2157299) | Small molecule; ALK5/TβRI kinase inhibitor | ATP-competitive inhibition of ALK5 kinase → blocks SMAD2/3 phosphorylation → abolishes canonical TGF-β signaling | Hepatocellular carcinoma (HCC): phase 2 (RECOURSE) — OS improvement in subset. Glioblastoma: phase 2 with lomustine — OS improvement. NSCLC + pembrolizumab combination trials. Major concern: cardiac toxicity (hypertrophy) with continuous dosing → intermittent 2-weeks-on/2-off schedule used in clinical trials. |
| Vactosertib (EW-7197) | Small molecule; ALK5/ALK4 kinase inhibitor | Dual inhibitor of TGF-β and activin signaling; highly selective and orally bioavailable | Phase 1/2 trials in colorectal cancer, cholangiocarcinoma, and fibrodysplasia ossificans progressiva (FOP — ALK2 gain-of-function → heterotopic ossification) |
| Fresolimumab (GC1008) | Human anti-TGF-β1/2/3 pan-neutralizing monoclonal antibody | Neutralizes all three TGF-β isoforms; pan-blockade; long half-life IV administration | IPF: phase 2 (Lonzano 2011): small trial showed some benefit on HRCT scores; safety concerns (skin lesions, neoplasms). NSCLC with focal radiation (SBRT): pilot trial showed improved immune activation (abscopal-like effects). Not approved; limited by systemic side effects. |
| Bintrafusp alfa (M7824) | Bifunctional fusion protein: anti-PD-L1 IgG + TGF-β RII extracellular domain (TGF-β trap) | PD-L1 arm blocks checkpoint → disinhibits T cells; TGF-β trap arm sequesters tumor-microenvironment TGF-β → relieves immunosuppression and EMT. Designed to deliver TGF-β blockade locally at PD-L1+ tumor sites | JAVELIN Bladder 100 phase 3 — did not improve OS vs avelumab. NSCLC first-line phase 3 (INTR@PID Lung 037) — did not improve PFS vs pembrolizumab. Biliary tract cancer: phase 2 showed activity. Research ongoing in HPV+ cancers (cervical, HNSCC) where TGF-β immunosuppression is dominant. |
| Pirfenidone | Small molecule; indirect TGF-β suppression | Inhibits TGF-β-stimulated collagen synthesis, myofibroblast differentiation, and PDGF-mediated fibroblast proliferation; also anti-TNF-α and anti-oxidant; mechanism imprecisely defined | IPF: approved 2014 (see fibrosis.html). Cardiac fibrosis post-MI: PIROUETTE trial (phase 2 RCT, n=116): pirfenidone 2403 mg/day × 52 weeks → reduction in extracellular volume fraction on CMR (−0.44% vs +0.47% placebo, p=0.048). Signals of efficacy in HFpEF-related fibrosis. |
| Lorecivivint (SM04690) | CLK2/DYRK1A kinase inhibitor; indirect Wnt/TGF-β modulator | Inhibits CLK2 → reduced SMAD2/3 phosphorylation; also activates β-catenin cartilage anabolic effects; cartilage-protective via dual Wnt-activating and TGF-β-suppressing actions | Osteoarthritis: phase 2 (STRIDES-OA) intra-articular injection — reduced cartilage loss and pain vs saline at 1 year. Phase 3 (STRIDES 3) ongoing. |
Connections
- drivesFibrosis — TGF-β1 is the master profibrotic mediator in IPF, liver cirrhosis, cardiac fibrosis, renal IFTA, and scleroderma; SMAD2/3 → Col1A1/α-SMA transcription is the core fibrogenic signal
- injuresLung Alveolus — in ARDS and IPF, TGF-β1 released from injured AT2 cells and alveolar macrophages drives barrier disruption (acute) and subsequent fibroproliferation (chronic) in the alveolar compartment
- amplified-byNLRP3 Inflammasome — IL-1β (produced downstream of NLRP3) potently induces TGF-β1 production in macrophages and epithelial cells; NLRP3 and TGF-β form a feed-forward loop amplifying both inflammation and fibrosis
- late-driver-ofARDS — TGF-β1 is acutely immunosuppressive on alveolar macrophages (reducing early injury) but dominates the fibroproliferative phase of DAD; dual role makes TGF-β a complex therapeutic target in ARDS
- endpoint-ofCKD — TGF-β/SMAD3 drives pericyte-to-myofibroblast transition in the renal interstitium; TGF-β1 is the principal mediator of tubular atrophy and interstitial fibrosis in all forms of CKD
- occurs-inSkin — TGF-β/SMAD3 drives dermal fibrosis in scleroderma via fibroblast activation; also essential for normal skin wound healing (keratinocyte migration, dermal repair) when transiently activated
- regulatesGerminal Center — TGF-β drives class switching to IgA in mucosal germinal centers (with IL-10); simultaneously suppresses Tfh cell function and germinal center reactions via Foxp3+ Treg induction — balancing humoral immunity at mucosal surfaces
- amplifiesCytokine Storm — paradoxically, TGF-β can contribute to cytokine storm environments indirectly via Th17 promotion (TGF-β + IL-6) and via tissue damage that releases further DAMPs; sustained TGF-β in COVID-19 ARDS correlates with poor outcomes and persistent fibrosis
References
- Massagué J. TGFβ signalling in context. Nat Rev Mol Cell Biol. 2012;13(10):616–30. doi:10.1038/nrm3434
- Derynck R, Turley SJ, Akhurst RJ. TGFβ biology in cancer progression and immunotherapy. Nat Rev Clin Oncol. 2021;18(1):9–34. doi:10.1038/s41571-020-0403-1
- Hinz B. Myofibroblasts. Exp Eye Res. 2016;142:56–70. doi:10.1016/j.exer.2015.07.009
- Travis MA, Sheppard D. TGF-β activation and function in immunity. Annu Rev Immunol. 2014;32:51–82. doi:10.1146/annurev-immunol-032713-120257
- Bierie B, Moses HL. Tumour microenvironment: TGFβ: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer. 2006;6(7):506–20. doi:10.1038/nrc1926
- Akhurst RJ, Hata A. Targeting the TGFβ signalling pathway in disease. Nat Rev Drug Discov. 2012;11(10):790–811. doi:10.1038/nrd3810
- Heldin CH, Moustakas A. Signaling receptors for TGF-β family members. Cold Spring Harb Perspect Biol. 2016;8(8):a022053. doi:10.1101/cshperspect.a022053
- Kamato D, Burch ML, Piva TJ, et al. Transforming growth factor-β signalling: role and consequences of Smad linker region phosphorylation. Cell Signal. 2013;25(10):2017–24. doi:10.1016/j.cellsig.2013.06.001